肺癌放疗前靶区勾画的PET/CT应用
本文综述了放疗在肺癌多模式治疗中的地位,以及标准形态学影像(CT、MR)用于分期和放疗计划的现状;并阐述PET通过可视化和定量葡萄糖代谢等分子过程克服标准影像局限、用于肺癌放疗计划的临床价值与方法学技术进展。
要点
- 放疗是肺癌多模式治疗的标志性手段之一,可与手术等局部治疗及化疗、酪氨酸激酶抑制剂、免疫检查点抑制剂等系统治疗联合。
- CT、MR等常规形态学影像常用于分期、疗效评估及放疗计划,而PET等先进影像技术正不断增加进入临床常规。
- PET可可视化和定量葡萄糖代谢等分子过程,克服标准影像技术的局限,对放疗计划具有相关性。
核心结论
- 本文综述放疗在肺癌治疗方案中的当前地位,阐明标准形态学影像用于分期和放疗计划的现有概念,并呈现PET-based放疗计划在临床背景中的位置及当前方法学/技术进展对肺癌放疗计划的潜在作用。
研究设计与样本
- 综述类文章,检索范围原文未报告。
主要发现
- 放疗/放射肿瘤学是肺癌多模式治疗的标志性手段之一,可与手术等局部治疗并列或联合,也可与化疗、酪氨酸激酶抑制剂和免疫检查点抑制剂等系统治疗联合。
- CT或MR等常规形态学影像常用于分期、疗效评估,也用于放疗计划。
- PET等先进影像技术正不断增加进入临床常规,通过可视化和定量葡萄糖代谢等分子过程克服标准影像技术的局限,这对放疗计划也具有相关性。
- 本文还讨论了当前方法学/技术进展,这些进展包含对肺癌患者放疗计划的潜在作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In clinical routine of patients suffering from lung cancer, radiotherapy/radiation oncology represents one of the therapeutic hallmarks in the multimodal treatment besides or in combination with other local treatments such as surgery, but also systemic treatments such as chemotherapy, tyrosine kinase, and immune check-point inhibitors. Conventional morphological imagings such as CT or MR are commonly used for staging, response assessment, but also for radiotherapy planning. However, advanced imaging techniques such as PET do continuously get increasing access to clinical routine overcoming limitations of standard imaging techniques by visualizing and quantifying molecular processes such as glucose metabolism, which is also of relevance for radiotherapy planning. This review article summarizes the current place of radiotherapy within the treatment regimens of patients with lung cancer and elucidates current concepts of standard morphological imaging for staging and radiotherapy planning. Moreover, the place of PET-based radiotherapy planning in a clinical context is presented and current methodological/technical advances that do comprise a potential role for radiotherapy planning in lung cancer patients are discussed.
引用
- Manapov F, Eze C, Holzgreve A, et al. PET/CT for Target Delineation of Lung Cancer Before Radiation Therapy. Semin Nucl Med. 2022. PMID: 35781392. doi:10.1053/j.semnuclmed.2022.05.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。